NLRP3 and early-onset autosomal dominant Alzheimer disease: In a mouse model of Alzheimer's disease, the oral NLRP3 inflammasome inhibitor, OLT1177, improved learning and memory deficits in the Morris water maze, restored LTP deficits in Schaffer collateral synapses, and reduced microglial reactivity (Lonnemann et al. 2020).